Argenx Projects 2026 Operating Expenses at $4 Billion Amid U.S. Expansion Plans
Argenx (ARGX) has outlined its financial trajectory, projecting operating expenses of approximately $4 billion for 2026. This increased spending is driven by a strategic roadmap that includes up to five product launches in the United States scheduled for 2027. CEO Karen Massey emphasized that the company remains in the early stages of capturing market potential for its lead product, VYVGART, across Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Following positive Phase III ALKIVIA results, the company is also exploring expansion into the rheumatology sector to broaden its therapeutic reach.
Tickers: $ARGX
Topics: clinical trial results drug launch earnings call pipeline expansion